CN106798755A - A kind of probiotic composition and its application with conditioning breast hyperplasia function - Google Patents
A kind of probiotic composition and its application with conditioning breast hyperplasia function Download PDFInfo
- Publication number
- CN106798755A CN106798755A CN201710141647.XA CN201710141647A CN106798755A CN 106798755 A CN106798755 A CN 106798755A CN 201710141647 A CN201710141647 A CN 201710141647A CN 106798755 A CN106798755 A CN 106798755A
- Authority
- CN
- China
- Prior art keywords
- probiotic composition
- probiotics
- medical extract
- chinese medical
- parts
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000006041 probiotic Substances 0.000 title claims abstract description 98
- 235000018291 probiotics Nutrition 0.000 title claims abstract description 98
- 239000000203 mixture Substances 0.000 title claims abstract description 60
- 230000000529 probiotic effect Effects 0.000 title claims abstract description 55
- 230000003750 conditioning effect Effects 0.000 title claims abstract description 29
- 206010006256 Breast hyperplasia Diseases 0.000 title claims abstract description 28
- 239000003814 drug Substances 0.000 claims abstract description 47
- 238000002360 preparation method Methods 0.000 claims abstract description 38
- 239000000284 extract Substances 0.000 claims abstract description 36
- 240000001046 Lactobacillus acidophilus Species 0.000 claims abstract description 27
- 235000013956 Lactobacillus acidophilus Nutrition 0.000 claims abstract description 27
- 229940039695 lactobacillus acidophilus Drugs 0.000 claims abstract description 27
- 241000186000 Bifidobacterium Species 0.000 claims abstract description 26
- 240000006024 Lactobacillus plantarum Species 0.000 claims abstract description 22
- 235000013965 Lactobacillus plantarum Nutrition 0.000 claims abstract description 22
- 229940072205 lactobacillus plantarum Drugs 0.000 claims abstract description 22
- 241001465754 Metazoa Species 0.000 claims abstract description 21
- 235000013406 prebiotics Nutrition 0.000 claims abstract description 21
- 239000000047 product Substances 0.000 claims description 27
- 241000894006 Bacteria Species 0.000 claims description 24
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 19
- 239000000843 powder Substances 0.000 claims description 17
- 210000000481 breast Anatomy 0.000 claims description 16
- 239000000463 material Substances 0.000 claims description 15
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 claims description 12
- 239000000706 filtrate Substances 0.000 claims description 12
- 239000000945 filler Substances 0.000 claims description 11
- 239000012467 final product Substances 0.000 claims description 10
- 241000208340 Araliaceae Species 0.000 claims description 9
- 241000512259 Ascophyllum nodosum Species 0.000 claims description 9
- 235000005035 Panax pseudoginseng ssp. pseudoginseng Nutrition 0.000 claims description 9
- 235000003140 Panax quinquefolius Nutrition 0.000 claims description 9
- 244000197580 Poria cocos Species 0.000 claims description 9
- 235000008599 Poria cocos Nutrition 0.000 claims description 9
- 235000008434 ginseng Nutrition 0.000 claims description 9
- 239000007787 solid Substances 0.000 claims description 8
- HEBKCHPVOIAQTA-NGQZWQHPSA-N d-xylitol Chemical compound OC[C@H](O)C(O)[C@H](O)CO HEBKCHPVOIAQTA-NGQZWQHPSA-N 0.000 claims description 7
- 229940079593 drug Drugs 0.000 claims description 7
- 238000000034 method Methods 0.000 claims description 7
- 239000012530 fluid Substances 0.000 claims description 6
- 238000004108 freeze drying Methods 0.000 claims description 6
- 239000006228 supernatant Substances 0.000 claims description 5
- 241000196324 Embryophyta Species 0.000 claims description 4
- 235000013399 edible fruits Nutrition 0.000 claims description 4
- 239000005913 Maltodextrin Substances 0.000 claims description 3
- 229920002774 Maltodextrin Polymers 0.000 claims description 3
- 229940035034 maltodextrin Drugs 0.000 claims description 3
- 238000001694 spray drying Methods 0.000 claims description 3
- 150000005846 sugar alcohols Chemical class 0.000 claims description 3
- 239000011885 synergistic combination Substances 0.000 claims description 3
- 241000193830 Bacillus <bacterium> Species 0.000 claims description 2
- 230000008901 benefit Effects 0.000 claims description 2
- 238000007873 sieving Methods 0.000 claims description 2
- FRXSZNDVFUDTIR-UHFFFAOYSA-N 6-methoxy-1,2,3,4-tetrahydroquinoline Chemical compound N1CCCC2=CC(OC)=CC=C21 FRXSZNDVFUDTIR-UHFFFAOYSA-N 0.000 claims 1
- 238000000605 extraction Methods 0.000 claims 1
- 238000001914 filtration Methods 0.000 claims 1
- RJKFOVLPORLFTN-LEKSSAKUSA-N Progesterone Chemical class C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](C(=O)C)[C@@]1(C)CC2 RJKFOVLPORLFTN-LEKSSAKUSA-N 0.000 abstract description 16
- 239000000262 estrogen Substances 0.000 abstract description 15
- 229940011871 estrogen Drugs 0.000 abstract description 14
- 230000036541 health Effects 0.000 abstract description 11
- 230000009286 beneficial effect Effects 0.000 abstract description 8
- 230000000968 intestinal effect Effects 0.000 abstract description 5
- 239000000583 progesterone congener Substances 0.000 abstract description 4
- 238000013329 compounding Methods 0.000 abstract description 2
- 210000005075 mammary gland Anatomy 0.000 description 35
- 230000006870 function Effects 0.000 description 25
- 230000035755 proliferation Effects 0.000 description 23
- 230000000694 effects Effects 0.000 description 14
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 12
- 241000699666 Mus <mouse, genus> Species 0.000 description 11
- 201000010099 disease Diseases 0.000 description 10
- 206010020718 hyperplasia Diseases 0.000 description 10
- 206010006187 Breast cancer Diseases 0.000 description 9
- 208000026310 Breast neoplasm Diseases 0.000 description 9
- 210000001519 tissue Anatomy 0.000 description 9
- 230000001580 bacterial effect Effects 0.000 description 8
- 229940088597 hormone Drugs 0.000 description 8
- 239000005556 hormone Substances 0.000 description 8
- 239000007788 liquid Substances 0.000 description 7
- VOXZDWNPVJITMN-ZBRFXRBCSA-N 17β-estradiol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 VOXZDWNPVJITMN-ZBRFXRBCSA-N 0.000 description 6
- 239000002609 medium Substances 0.000 description 6
- 238000010172 mouse model Methods 0.000 description 6
- 239000000186 progesterone Substances 0.000 description 6
- 229960003387 progesterone Drugs 0.000 description 6
- 230000028327 secretion Effects 0.000 description 6
- 230000002124 endocrine Effects 0.000 description 5
- 239000003223 protective agent Substances 0.000 description 5
- 238000012360 testing method Methods 0.000 description 5
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 4
- 241000186660 Lactobacillus Species 0.000 description 4
- 241000699670 Mus sp. Species 0.000 description 4
- 230000003078 antioxidant effect Effects 0.000 description 4
- 229930182833 estradiol Natural products 0.000 description 4
- 229960005309 estradiol Drugs 0.000 description 4
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 4
- 229940039696 lactobacillus Drugs 0.000 description 4
- 210000004185 liver Anatomy 0.000 description 4
- 230000002611 ovarian Effects 0.000 description 4
- 208000024891 symptom Diseases 0.000 description 4
- 239000003963 antioxidant agent Substances 0.000 description 3
- 230000033228 biological regulation Effects 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 201000011510 cancer Diseases 0.000 description 3
- 239000012153 distilled water Substances 0.000 description 3
- 238000005516 engineering process Methods 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 238000000855 fermentation Methods 0.000 description 3
- 230000004151 fermentation Effects 0.000 description 3
- 230000003054 hormonal effect Effects 0.000 description 3
- 230000006872 improvement Effects 0.000 description 3
- 244000005700 microbiome Species 0.000 description 3
- 230000000116 mitigating effect Effects 0.000 description 3
- 238000004321 preservation Methods 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 238000011084 recovery Methods 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 210000001835 viscera Anatomy 0.000 description 3
- 229920001817 Agar Polymers 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- 102000009151 Luteinizing Hormone Human genes 0.000 description 2
- 108010073521 Luteinizing Hormone Proteins 0.000 description 2
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 2
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 239000008272 agar Substances 0.000 description 2
- 206010003549 asthenia Diseases 0.000 description 2
- 230000017531 blood circulation Effects 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 230000007423 decrease Effects 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000000857 drug effect Effects 0.000 description 2
- 235000013305 food Nutrition 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- 235000011187 glycerol Nutrition 0.000 description 2
- 230000002218 hypoglycaemic effect Effects 0.000 description 2
- 238000011081 inoculation Methods 0.000 description 2
- 239000002054 inoculum Substances 0.000 description 2
- 239000007928 intraperitoneal injection Substances 0.000 description 2
- 239000004310 lactic acid Substances 0.000 description 2
- 235000014655 lactic acid Nutrition 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 230000008520 organization Effects 0.000 description 2
- 230000027758 ovulation cycle Effects 0.000 description 2
- 230000001717 pathogenic effect Effects 0.000 description 2
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 2
- 229920000053 polysorbate 80 Polymers 0.000 description 2
- 230000001737 promoting effect Effects 0.000 description 2
- 239000002994 raw material Substances 0.000 description 2
- QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 description 2
- 235000020183 skimmed milk Nutrition 0.000 description 2
- 150000003384 small molecules Chemical class 0.000 description 2
- 241000894007 species Species 0.000 description 2
- 210000000952 spleen Anatomy 0.000 description 2
- 230000001954 sterilising effect Effects 0.000 description 2
- 229960004793 sucrose Drugs 0.000 description 2
- 210000001541 thymus gland Anatomy 0.000 description 2
- 210000004291 uterus Anatomy 0.000 description 2
- 206010061623 Adverse drug reaction Diseases 0.000 description 1
- 208000019901 Anxiety disease Diseases 0.000 description 1
- UYIFTLBWAOGQBI-BZDYCCQFSA-N Benzhormovarine Chemical compound C([C@@H]1[C@@H](C2=CC=3)CC[C@]4([C@H]1CC[C@@H]4O)C)CC2=CC=3OC(=O)C1=CC=CC=C1 UYIFTLBWAOGQBI-BZDYCCQFSA-N 0.000 description 1
- 206010010774 Constipation Diseases 0.000 description 1
- 208000030453 Drug-Related Side Effects and Adverse reaction Diseases 0.000 description 1
- 206010062717 Increased upper airway secretion Diseases 0.000 description 1
- 229910021578 Iron(III) chloride Inorganic materials 0.000 description 1
- 201000010538 Lactose Intolerance Diseases 0.000 description 1
- 102000010909 Monoamine Oxidase Human genes 0.000 description 1
- 108010062431 Monoamine oxidase Proteins 0.000 description 1
- 206010028813 Nausea Diseases 0.000 description 1
- 208000029082 Pelvic Inflammatory Disease Diseases 0.000 description 1
- 239000001888 Peptone Substances 0.000 description 1
- 108010080698 Peptones Proteins 0.000 description 1
- 241000220317 Rosa Species 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 1
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 208000031971 Yin Deficiency Diseases 0.000 description 1
- VLSOAXRVHARBEQ-UHFFFAOYSA-N [4-fluoro-2-(hydroxymethyl)phenyl]methanol Chemical compound OCC1=CC=C(F)C=C1CO VLSOAXRVHARBEQ-UHFFFAOYSA-N 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 230000036506 anxiety Effects 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 235000015278 beef Nutrition 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 208000030270 breast disease Diseases 0.000 description 1
- 210000005252 bulbus oculi Anatomy 0.000 description 1
- 239000001110 calcium chloride Substances 0.000 description 1
- 229910001628 calcium chloride Inorganic materials 0.000 description 1
- 229940041514 candida albicans extract Drugs 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 210000004913 chyme Anatomy 0.000 description 1
- 230000009514 concussion Effects 0.000 description 1
- 210000002808 connective tissue Anatomy 0.000 description 1
- 235000013365 dairy product Nutrition 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000006837 decompression Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 235000015872 dietary supplement Nutrition 0.000 description 1
- AIUDWMLXCFRVDR-UHFFFAOYSA-N dimethyl 2-(3-ethyl-3-methylpentyl)propanedioate Chemical compound CCC(C)(CC)CCC(C(=O)OC)C(=O)OC AIUDWMLXCFRVDR-UHFFFAOYSA-N 0.000 description 1
- ZPWVASYFFYYZEW-UHFFFAOYSA-L dipotassium hydrogen phosphate Chemical compound [K+].[K+].OP([O-])([O-])=O ZPWVASYFFYYZEW-UHFFFAOYSA-L 0.000 description 1
- 229910000396 dipotassium phosphate Inorganic materials 0.000 description 1
- 208000002173 dizziness Diseases 0.000 description 1
- 210000004696 endometrium Anatomy 0.000 description 1
- 239000002158 endotoxin Substances 0.000 description 1
- 210000000981 epithelium Anatomy 0.000 description 1
- 235000013373 food additive Nutrition 0.000 description 1
- 239000002778 food additive Substances 0.000 description 1
- 230000005714 functional activity Effects 0.000 description 1
- 210000004907 gland Anatomy 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 210000003016 hypothalamus Anatomy 0.000 description 1
- 230000036737 immune function Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000002779 inactivation Effects 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 206010022437 insomnia Diseases 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 208000019423 liver disease Diseases 0.000 description 1
- 230000005976 liver dysfunction Effects 0.000 description 1
- 230000029849 luteinization Effects 0.000 description 1
- 229910001629 magnesium chloride Inorganic materials 0.000 description 1
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 1
- 235000019341 magnesium sulphate Nutrition 0.000 description 1
- 229940099596 manganese sulfate Drugs 0.000 description 1
- 239000011702 manganese sulphate Substances 0.000 description 1
- 235000007079 manganese sulphate Nutrition 0.000 description 1
- SQQMAOCOWKFBNP-UHFFFAOYSA-L manganese(II) sulfate Chemical compound [Mn+2].[O-]S([O-])(=O)=O SQQMAOCOWKFBNP-UHFFFAOYSA-L 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 238000013160 medical therapy Methods 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 230000008693 nausea Effects 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 235000019198 oils Nutrition 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 235000019319 peptone Nutrition 0.000 description 1
- 230000000737 periodic effect Effects 0.000 description 1
- 208000026435 phlegm Diseases 0.000 description 1
- 230000001766 physiological effect Effects 0.000 description 1
- 230000001072 progestational effect Effects 0.000 description 1
- 230000000750 progressive effect Effects 0.000 description 1
- 230000002062 proliferating effect Effects 0.000 description 1
- 108010009004 proteose-peptone Proteins 0.000 description 1
- 210000003456 pulmonary alveoli Anatomy 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000009711 regulatory function Effects 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 230000001850 reproductive effect Effects 0.000 description 1
- 210000004994 reproductive system Anatomy 0.000 description 1
- 239000012266 salt solution Substances 0.000 description 1
- 238000007789 sealing Methods 0.000 description 1
- 239000013049 sediment Substances 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 229940076279 serotonin Drugs 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 239000001632 sodium acetate Substances 0.000 description 1
- 235000017281 sodium acetate Nutrition 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 230000008337 systemic blood flow Effects 0.000 description 1
- 238000012549 training Methods 0.000 description 1
- YWYZEGXAUVWDED-UHFFFAOYSA-N triammonium citrate Chemical compound [NH4+].[NH4+].[NH4+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O YWYZEGXAUVWDED-UHFFFAOYSA-N 0.000 description 1
- 238000009777 vacuum freeze-drying Methods 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
- 239000012138 yeast extract Substances 0.000 description 1
- NWONKYPBYAMBJT-UHFFFAOYSA-L zinc sulfate Chemical compound [Zn+2].[O-]S([O-])(=O)=O NWONKYPBYAMBJT-UHFFFAOYSA-L 0.000 description 1
- 229910000368 zinc sulfate Inorganic materials 0.000 description 1
- 239000011686 zinc sulphate Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
- A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
- A61K35/747—Lactobacilli, e.g. L. acidophilus or L. brevis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/702—Oligosaccharides, i.e. having three to five saccharide radicals attached to each other by glycosidic linkages
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
- A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
- A61K35/745—Bifidobacteria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/02—Algae
- A61K36/03—Phaeophycota or phaeophyta (brown algae), e.g. Fucus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/06—Fungi, e.g. yeasts
- A61K36/07—Basidiomycota, e.g. Cryptococcus
- A61K36/076—Poria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/25—Araliaceae (Ginseng family), e.g. ivy, aralia, schefflera or tetrapanax
- A61K36/258—Panax (ginseng)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/75—Rutaceae (Rue family)
- A61K36/752—Citrus, e.g. lime, orange or lemon
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/331—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using water, e.g. cold water, infusion, tea, steam distillation, decoction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/39—Complex extraction schemes, e.g. fractionation or repeated extraction steps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/50—Methods involving additional extraction steps
- A61K2236/51—Concentration or drying of the extract, e.g. Lyophilisation, freeze-drying or spray-drying
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Alternative & Traditional Medicine (AREA)
- Botany (AREA)
- Medical Informatics (AREA)
- Molecular Biology (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
The invention discloses a kind of probiotic composition with conditioning breast hyperplasia function, it is made up of Lactobacillus plantarum, lactobacillus acidophilus and animal bifidobacteria；In the probiotic composition, the content of Lactobacillus plantarum is 5 × 106‑5×109CFU/g, the content of lactobacillus acidophilus is 2.5 × 106‑2.5×109CFU/g, the content of animal bifidobacteria is 2.5 × 106‑2.5×109CFU/g.Above-mentioned probiotic composition is also cooperateed with prescription by the present invention with Chinese medical extract, is made probiotics Chinese medicine preparation.Further, the components such as probiotic composition, Chinese medical extract and prebiotics compounding is made the product with conditioning breast hyperplasia function by the present invention.Probiotic composition of the invention, probiotics Chinese medicine preparation and product can promote propagation of the probiotics in human body, recover Estrogen and progestin balance, and human body intestinal canal flora is adjusted while cyclomastopathy is alleviated, and be beneficial to health.
Description
Technical field
The present invention relates to biomedicine field, more particularly to a kind of probiotic combinations with conditioning breast hyperplasia function
Thing and its application.
Background technology
According to the latest survey of the World Health Organization, women of the world more than 80%, the mammary gland disease with not degree, mammary gland
Cancer has developed into the malignant tumour of global incidence first, and the whole world there are about 1,200,000 women and suffers from breast cancer every year, and 500,000 people die from
Breast cancer, fatal rate is more than 41%.And since the nineties, the breast cancer incidence growth rate of China is the twice in the whole world
Many, urban area is especially pronounced.Chinese Breast Cancer whole year detection number is the half in Europe, substantially suitable with the U.S..If this
One trend keeps constant, and by 2021, Chinese breast cancer patients will be up to 2,500,000, and the incidence of disease will be from less than 60/100,000 women
Increase to above 100/100,000 women.And the generation development of breast cancer is a slow process, the proliferation of mammary gland is breast cancer
The major reason of generation.
Cyclomastopathy refers to breast epithelium and proliferation of fibrous tissue, breast tissue conduit and newborn leaflet moving back in structure
The change of row venereal disease and the growth of progressive connective tissue, its pathogenic factor are lacked of proper care mainly due to endocrine hormone.Cyclomastopathy
It is the most common breast disease of women, its incidence of disease accounts for the first place of mammary gland disease.The sick incidence of disease was in and rose year by year in the last few years
Trend, the age also increasingly becomes younger.There are about 70%~80% women according to investigations has the different degrees of proliferation of mammary gland, many
See the women of 25~45 years old.
Modern medicine study shows that female breast is the target organ of internal various endocrine hormones, and breast grows,
And its cyclically-varying that occurs with menstrual cycle in each stage and a series of physiological activities such as galactosis, it is by brain skin
The regulation and control of layer, hypothalamus and various incretory.The generation development of mammary gland is closely related with ovarian endocrine state, breast tissue
As endometrium, by ovarian endocrine periodic adjustment, and corresponding cyclically-varying is produced, therefore, breast there is also
Corresponding propagation and the periodically-varied for returing to the past.The ratio of ovarian secretion estrogen and progestational hormone is to determine whether women suffers from mammary gland
Hyperplasia and the key factor for suffering from gland cancer.Under normal circumstances, both are in the state of relative equilibrium in women body, with the menstrual cycle
Changing again and again, breast under both functionss of hormones, hyperplasia → recovery → hyperplasia → restore again, if this
The secretion of two kinds of hormones gets muddled, preovulatory phase lutropin (LH) and estradiol (E2) hyposecretion, and luteal phase
Estradiol definitely or relatively increases, progesterone (P) Secretion pair or definitely not enough, loses restriction estradiol and protects breast tissue
Effect, makes breast tissue constantly be among the stimulation of estrogen, and the breast tissue meromorphosis of normal hyperplasia just forms pathology
The proliferation of mammary gland of property, i.e. cyclomastopathy.
So, western medicine cyclomastopathy is mainly regulation ovarian endocrine and tends to normal or blocking hormonal action target
Point, thus it is many using suppression estrogen drugs.But because its side effect is larger, patient often causes paramenia, body after taking
Increase or decrease again, nausea is dizzy, heating, insomnia, or even the symptom such as liver dysfunction, therefore it is unsuitable as the treatment proliferation of mammary gland
The main method of disease.
The Chinese traditional treatment proliferation of mammary gland has a long history, and the traditional Chinese medical science thinks that the treatment proliferation of mammary gland is main from the following aspects
Carry out：(1) dispersing stagnated hepatoqi, harmonizing the functional activities of vital QI；(2) it is promoting blood circulation and removing blood stasis, the newborn network of dredging；3) resolving phlegm and softening hard masses, dispersing swelling and dissipating binds.But Chinese traditional treatment
Longer cycle is generally required, is taken effect slow.Therefore, how to nurse one's health internal system recovery by safely and effectively method is normally
The research direction of the Modern medical therapy proliferation of mammary gland and other relevant diseases.
Probiotics is the class active microorganism beneficial to host, is colonized in human body intestinal canal, reproductive system, can be produced
Definite health efficacy is so as to the active beneficial microorganism general name for improving host's microecological balance, playing beneficial effect.It is state
The security food additives generally acknowledged on border, are widely used to dairy products, health products and pharmaceuticals industry, are mainly used in adjusting intestines
Road function, reduce blood cholesterol levels, prevent harmful substance generation, delaying human body caducity, regulation immune function of human body, suppress
Lactose intolerance, antitumor action etc..Whether probiotics can also have adjustment effect to estrogen and its metabolite, be subject to
The extensive concern of domestic and foreign scholars.2012, the first passage human trial such as Flores confirmed that enteric microorganism can be adjusted
Organism estrogen level.Research in recent years to probiotics conditioning hormonal readiness is also more and more, and its main mechanism includes contracting
The time of chyme emptying in short enteron aisle, so as to reduce again receipts of the estrogen in enteron aisle；Serotonin level in regulating intestinal canal,
So as to alleviate anxiety, the risk for reducing and suffering from the proliferation of mammary gland is improved the health care of sleep；Reduce endotoxin content, liver protecting in enteron aisle
Etc. aspect.But being not yet related to probiotics at present has the report for the treatment of proliferation of mammary gland aspect effect.
The content of the invention
For above-mentioned the deficiencies in the prior art, it is an object of the invention to provide a kind of with conditioning breast hyperplasia function
Probiotic composition.Probiotic composition of the invention can nurse one's health estrogen and progesterone level, have to breast cancer hyperplasia disease
There is good mitigation.
Another object of the present invention is to provide a kind of probiotics Chinese medicine preparation with conditioning breast hyperplasia function, pass through
Probiotics and Chinese medicine use in conjunction, synergy are significantly enhanced into the treatment curative effect to the proliferation of mammary gland.
To achieve the above object, the present invention is adopted the following technical scheme that：
The first aspect of the present invention, there is provided a kind of probiotic composition with conditioning breast hyperplasia function, by plant breast
Bacillus, lactobacillus acidophilus and animal bifidobacteria composition；
In the probiotic composition, the content of Lactobacillus plantarum is 5 × 106-5×109CFU/g, lactobacillus acidophilus contains
Measure is 2.5 × 106-2.5×109CFU/g, the content of animal bifidobacteria is 2.5 × 106-2.5×109CFU/g。
Preferably, in the probiotic composition, the mass ratio of Lactobacillus plantarum, lactobacillus acidophilus and animal bifidobacteria
It is 2:1:1.
It is further preferred that the lactobacillus acidophilus is deposit number CCTCC NO:The lactobacillus acidophilus of M2015129
(Lactobacillus acidophilus)BLCC2-0024；The Lactobacillus plantarum is deposit number CCTCC M2010150
Lactobacillus plantarum LP.
The present invention also provides the preparation method of above-mentioned probiotic composition, and step is as follows：
(1) Lactobacillus plantarum, lactobacillus acidophilus and animal bifidobacteria are carried out into fermented and cultured respectively, makes bacterium in zymotic fluid
Bulk concentration reaches exponential phase 0.5-2.0 × 109cfu/ml；
(2) zymotic fluid is centrifuged respectively, abandons supernatant, obtain Lactobacillus plantarum, lactobacillus acidophilus and animal bifidobacteria
Bacterium mud；
(3) bacterium mud is well mixed with freeze drying protectant, freeze-drying is obtained final product.
The second aspect of the present invention, there is provided a kind of probiotics Chinese medicine preparation with conditioning breast hyperplasia function, by above-mentioned
Probiotic composition and Chinese medical extract synergistic combination are formed.
The Chinese medical extract is made up of the bulk drug of following weight portion：
Ginseng 3-8 parts, Poria cocos 10-15 parts, kelp 10-12 parts, dried orange peel 8-12 parts.
Preferably, the Chinese medical extract is made up of the bulk drug of following weight portion：
6 parts of ginseng, 12 parts of Poria cocos, 12 parts of kelp, 10 parts of dried orange peel.
The preparation method of the Chinese medical extract is as follows：
Ginseng, Poria cocos, kelp and dried orange peel are placed in 8-10 times of water and soak 40-60min, decocted, water continues to decoct after opening
30-50min, is filtrated to get the first filtrate；The dregs of a decoction carry out secondary decoction with 6-8 times of water, and water continues to decoct 30-50min, mistake after opening
Filter obtains the second filtrate and is well mixed with the first filtrate, and it is more than 30% to be concentrated into solid content, and spray drying is crushed, mistake
Sieve, obtains final product Chinese medical extract.
Preferably, in above-mentioned probiotics Chinese medicine preparation, the weight ratio of the probiotic composition and Chinese medical extract is (2-
10)：(20-30).
Above-mentioned probiotic composition and/or probiotics Chinese medicine preparation are in the product with conditioning breast hyperplasia function is prepared
Purposes be also protection scope of the present invention.
In such use, the product includes but is not limited to medicine, food or health products.
The third aspect of the present invention, there is provided a kind of product with conditioning breast hyperplasia function, by following mass percent
Component composition：
Probiotic composition 2-10%, Chinese medical extract 20-30%, prebiotics 30-40%, auxiliary material filler 30-40%.
The prebiotics is selected from one or more in oligoisomaltose, FOS and xylo-oligosaccharide；Preferably, institute
Prebiotics is stated by oligoisomaltose, FOS and xylo-oligosaccharide in mass ratio 4:3:1 composition.
The auxiliary material filler is selected from one or more in maltodextrin, citric acid, fruit powder and sugar alcohol.
The present invention also provides the preparation method of the above-mentioned product with conditioning breast hyperplasia function, and step is as follows：
(1) probiotic composition and Chinese medical extract are prepared as stated above；
(2) probiotic composition, Chinese medical extract, prebiotics and auxiliary material filler are well mixed, are obtained final product.
Beneficial effects of the present invention：
(1) present invention develops the new application of probiotics, and probiotic composition provided by the present invention can promote prebiotic
Propagation of the bacterium in human body, recovers Estrogen and progestin balance, and human body intestinal canal flora is adjusted while cyclomastopathy is alleviated, and has
Beneficial to health.
(2) probiotics Chinese medicine preparation provided by the present invention, is assisted by above-mentioned probiotic composition and Chinese medical extract
It is same to combine.Though the proliferation of mammary gland belongs to asthenia in origin and asthenia in superficiality disease, the interpretation of the cause, onset and process of an illness is ever-changing, only by simple kidney tonifying righting or blood circulation promoting and dispersing pathogen accumulation
It is inadequate, in probiotics Chinese medicine preparation of the invention, wherein, Chinese medical extract can suppress monoamine oxidase vigor, suppress
Collagenous fibres synthesize, and improve local (mammary gland, liver) and systemic blood circulation, are conducive to hormone to be metabolized in vivo, strengthen liver
To estrogen inactivation capacity, promotion organization reparation；Can also promote the secretion of lutropin, the excessive secretion of antagonising oestrogen,
Be intended to recover body in regulatory function, suppress breast tissue occur proliferative lesion；Probiotics can be by Chinese medical extract
Small-molecule substance preferably is resolved into, is conducive to the absorption of enteron aisle, Chinese medicine and probiotics reasonable compatibility, experiment proves that, it is prebiotic
The drug effect of bacterium Chinese medicine preparation overcomes that exclusive use Chinese medicine administration time is long, have medicine pair better than any raw material is used alone
The shortcoming of effect, both combine has synergy.
(3) present invention is provided alleviation or the product of improvement pelvic inflammation, are same by above-mentioned probiotic composition, medicine food
Source Chinese medicine, prebiotics and auxiliary material filler are prepared from, and on the basis of probiotics, Chinese medicine synergy, increased again prebiotic
First component, prebiotics as a kind of dietary supplements, by the growth for stimulating bacterium in a kind of or a small number of kind of bacterium colony of selectivity
With activity, and to host produce wholesome effect.The prebiotics component added in the present invention can be with probiotic combinations produce
Raw further synergy, so as to be more beneficial for improvement and mitigation to proliferation of mammary gland symptom.
(4) product with conditioning breast hyperplasia function of the invention, preparation process is simple, in Chinese medicine each effectively into
Divide loss less, it is safe, it is ensured that the stability between product batches.
Brief description of the drawings
The Figure of description for constituting the part of the application is used for providing further understanding of the present application, and the application's shows
Meaning property embodiment and its illustrated for explaining the application, does not constitute the improper restriction to the application.
Fig. 1：Influence to each group mammary gland of mouse structure.
Specific embodiment
It is noted that described further below is all exemplary, it is intended to provide further instruction to the application.Unless another
Indicate, all technologies used herein and scientific terminology are with usual with the application person of an ordinary skill in the technical field
The identical meanings of understanding.
It should be noted that term used herein above is merely to describe specific embodiment, and be not intended to restricted root
According to the illustrative embodiments of the application.As used herein, unless the context clearly indicates otherwise, otherwise singulative
Be also intended to include plural form, additionally, it should be understood that, when in this manual use term "comprising" and/or " bag
Include " when, it indicates existing characteristics, step, operation, device, component and/or combinations thereof.
As background technology is introduced, lacking can treat the probiotic composition of the proliferation of mammary gland in the prior art, be
Technical problem as above is solved, present applicant proposes a kind of probiotic composition with conditioning breast hyperplasia function.The benefit
Raw bacteria composition can nurse one's health estrogen and progesterone level, have good mitigation to breast cancer hyperplasia disease.
In a kind of embodiment of the application, there is provided a kind of probiotic combinations with conditioning breast hyperplasia function
Thing, is made up of Lactobacillus plantarum, lactobacillus acidophilus and animal bifidobacteria；
In the probiotic composition, the content of Lactobacillus plantarum is 5 × 106-5×109CFU/g, lactobacillus acidophilus contains
Measure is 2.5 × 106-2.5×109CFU/g, the content of animal bifidobacteria is 2.5 × 106-2.5×109CFU/g。
As one kind preferred embodiment, in the probiotic composition, Lactobacillus plantarum, lactobacillus acidophilus and animal
The mass ratio of Bifidobacterium is 2:1:1.
Because can also there is larger difference in the performance of the bacterial strain of the same race of separate sources, therefore, the application is in process of the test
Probiotics that species, same but different separation also to the probiotics in probiotic composition are originated and combinations thereof is adjusted
It is whole, as a result find, it is CCTCC NO with deposit number relative to other species or the probiotic combinations in source:M2015129's
Lactobacillus acidophilus (Lactobacillus acidophilus) BLCC2-0024, deposit number are the plant of CCTCC M2010150
The effect that thing lactobacillus LP and animal bifidobacteria are compounded is best.
The deposit number is CCTCC NO:Lactobacillus acidophilus (the Lactobacillus of M2015129
Acidophilus) BLCC2-0024 is preserved in China typical culture collection center on March 18th, 2015, and records special
In sharp " a kind of hypoglycemic probiotics preparation and preparation method thereof " (CN105039217A), prior art is constituted, therefore no longer provide
Preservation is proved.Bacterial strain function involved at present mainly has hypoglycemic and alleviates the elderly's YIN-deficiency type constipation, there is not yet it is used
In the report of the treatment proliferation of mammary gland.
The deposit number is preserved in China on June 21st, 2010 for the Lactobacillus plantarum LP of CCTCC M2010150
Type Tissue Collection, and record patent " a kind of to can be used for the lactic acid bacteria of biological preservation and its application "
(CN101914475A) in, prior art is constituted, therefore no longer providing preservation proves.Bacterial strain function involved at present is mainly
For the anti-corrosive fresh-keeping of fruit, there is not yet it is used to treat the report of the proliferation of mammary gland.
The animal bifidobacteria is conventional commercially available prod.
The selected above-mentioned three plants of bacterium of the application can promote propagation of the probiotics in human body, recover Estrogen and progestin and put down
Weighing apparatus, human body intestinal canal flora is adjusted while cyclomastopathy is alleviated, is beneficial to health.
The preparation method of above-mentioned probiotic composition, step is as follows：
(1) Lactobacillus plantarum, lactobacillus acidophilus and animal bifidobacteria are carried out into fermented and cultured respectively, makes bacterium in zymotic fluid
Bulk concentration reaches exponential phase 0.5-2.0 × 109cfu/ml；
(2) zymotic fluid is centrifuged respectively, abandons supernatant, obtain Lactobacillus plantarum, lactobacillus acidophilus and animal bifidobacteria
Bacterium mud；
(3) bacterium mud is well mixed with freeze drying protectant, freeze-drying is obtained final product.
Described strain protective agent can select strain protective agent generally in the art.
In a specific embodiment, described frozen-dried protective agent prescription is：Sucrose 8g, skimmed milk power 26g, glycerine 1mL,
Distilled water 100mL, 115 DEG C, sterilize 15min.
Preferably, the probiotic composition of gained carries out dispensing again after sieving.
Preferably, 80-100 mesh sieves are crossed.
In the another embodiment of the application, there is provided a kind of probiotics Chinese medicine with conditioning breast hyperplasia function
Preparation, is formed by above-mentioned probiotic composition and Chinese medical extract synergistic combination.
The Chinese medical extract is made up of the bulk drug of following weight portion：
Ginseng 3-8 parts, Poria cocos 10-15 parts, kelp 10-12 parts, dried orange peel 8-12 parts.
The preparation method of the Chinese medical extract is as follows：
Ginseng, Poria cocos, kelp and dried orange peel are placed in 8-10 times of water and soak 40-60min, decocted, water continues to decoct after opening
30-50min, is filtrated to get the first filtrate；The dregs of a decoction carry out secondary decoction with 6-8 times of water, and water continues to decoct 30-50min, mistake after opening
Filter obtains the second filtrate and is well mixed with the first filtrate, and it is more than 30% to be concentrated into solid content, and spray drying is crushed, mistake
Sieve, obtains final product Chinese medical extract.
As one kind preferred embodiment, in above-mentioned probiotics Chinese medicine preparation, the probiotic composition and Chinese medicine are carried
The weight ratio for taking thing is (2-10)：(20-30).
Chinese medical extract can preferably be resolved into small-molecule substance by probiotics, be conducive to the absorption of enteron aisle, Chinese medicine and
Probiotics reasonable compatibility, experiment proves that, the drug effect of probiotics Chinese medicine preparation overcomes list better than any raw material is used alone
Solely using Chinese medicine administration time it is long, have the shortcomings that drug side-effect, both combine have act synergistically.
In the yet another embodiment of the application, there is provided a kind of product with conditioning breast hyperplasia function, by with
The component composition of lower mass percent：
Probiotic composition 2-10%, Chinese medical extract 20-30%, prebiotics 30-40%, auxiliary material filler 30-40%.
The prebiotics is selected from one or more in oligoisomaltose, FOS and xylo-oligosaccharide；Preferably, institute
Prebiotics is stated by oligoisomaltose, FOS and xylo-oligosaccharide in mass ratio 4:3:1 composition.
The auxiliary material filler is selected from one or more in maltodextrin, citric acid, fruit powder and sugar alcohol.
The present invention also provides the preparation method of the above-mentioned product with conditioning breast hyperplasia function, and step is as follows：
(1) probiotic composition and Chinese medical extract are prepared as stated above；
(2) probiotic composition, Chinese medical extract, prebiotics and auxiliary material filler are well mixed, are obtained final product.
In order that obtaining those skilled in the art can clearly understand the technical scheme of the application, below with reference to tool
The embodiment of body describes the technical scheme of the application in detail.
Test material used is the conventional test material in this area in the embodiment of the present invention, can be by commercial channel
It is commercially available.
Embodiment 1：The preparation of the freeze-dried powder of probiotics
1) by Lactobacillus plantarum (deposit number be CCTCC M2010150), lactobacillus acidophilus, (deposit number is respectively
CCTCC NO:M2015129 after), animal bifidobacteria is activated through culture medium, it is inoculated in fermentation medium, concussion and cultivate makes
Cell concentration reaches exponential phase 0.5-2 × 109CFU/mL。
The preparation of lactobacillus seed liquor：Culture presevation pipe is taken out, flat board is drawn with MRS solid mediums and is recovered, 37 DEG C
Anaerobic culturel 48 hours.In picking single bacterium colony 100 milliliters of MRS culture mediums of inoculation under flat board, anaerobism training in 37 DEG C of incubators
Support 24 hours.Seed is seeded in the big triangular flasks of 3L (liquid amount is 2.5L), 37 DEG C of Anaerobic culturel 24- using 5% inoculum concentration
48 hours, its bacterial concentration is detected, bacterial content is more than 1,000,000,000/milliliter, you can terminate as lactobacillus liquid fermentation.Wherein, institute
The MRS culture mediums stated：Glucose 2.0%, ammonium citrate 0.2%, sodium acetate 0.5%, dipotassium hydrogen phosphate 0.5%, manganese sulfate
0.02%, magnesium sulfate 0.05%, peptone 1.0%, beef extract 1.0%, yeast extract 0.5%, Tween-80 0.1%, PH6.0；
Solid medium adds 1.5% agar powder, 0.1MPa sterilizings 15min.
The preparation of Bifidobacterium seed liquid：Culture presevation pipe is taken out, flat board is drawn with Bifidobacterium solid medium and is answered
Soviet Union, 37 DEG C Anaerobic culturel 48-72 hours.In picking single bacterium colony 50 milliliters of Medium of Bifidobacterium of inoculation under flat board, detesting
Cultivated 48 hours in oxygen incubator.Seed uses 5% inoculum concentration to be seeded in the big triangular flasks of 3L (liquid amount is 2.5L), with nothing
Bacterium vegetable oil carries out oil sealing, 37 degree Anaerobic culturel 36-48 hours, detect its bacterial concentration, bacterial content is 500,000,000/milliliter, you can made
It is the termination of Bifidobacterium liquid fermentation.Wherein, described Medium of Bifidobacterium is：Casein peptone 1%, soy peptone
0.5%, dusty yeast 0.25%, glucose 1.5%, K2HPO40.2%, MgCl2·6H2O 0.05%, CaCl20.015%,
ZnSO4·7H2O 0.025%, FeCl30.01%, L-cysteine hydrochloride 0.005%, (1000mL adds Tween-80 1mL
1mL), pH to 6.5, solid medium is adjusted to add 1.5% agar powder, 0.1MPa sterilizings 15min.
2) it is centrifuged after each strain fermentating liquid is mixed, abandons supernatant, bacterial sediment washing, centrifugation is abandoned supernatant, obtains bacterium mud.
3) prepare bacterium powder protective agent, be formulated for cane sugar content be 8g, skimmed milk power 26g, glycerine 1mL, distilled water 100mL,
115 DEG C, sterilize 15min.
4) bacterium powder protective agent and bacterium mud are sufficiently mixed, then by mixture pre-freeze, then carry out vacuum freeze drying, obtain work
Property probiotics dry powder.
(2) sieve
By the active probiotic dry powder of gained in step (1), 80-100 mesh sieves are crossed.
Bacterium powder is counted：The viable count of probiotics dry powder is measured using the method for plate culture count.
Embodiment 2：The preparation of Chinese medical extract
1) according to weight portion：Ginseng 6g, Poria cocos 12g, kelp 12g, dried orange peel 10g；
2) mixture is placed in 10 times of water and soaks 50min, decocted, water continues to decoct 40min after opening, and is filtrated to get first
Filtrate；The dregs of a decoction carry out secondary decoction with 8 times of water, and water continues to decoct 40min after opening, and is filtrated to get the second filtrate and is mixed with the first filtrate
Close uniform, be more than 30% to solid content by vacuum decompression Rotary Evaporators concentrated traditional Chinese medicine liquid, enter spray dryer,
140 DEG C of EAT control, 90 DEG C of leaving air temp, 45 revs/min of atomizer rotating speed, charging rate is 5ml/ minutes, must be sprayed
Xeraphium, crushes, and crosses 100 mesh above sieves and obtains final product Chinese medical extract.
Embodiment 3：The preparation of the probiotic composition with conditioning breast hyperplasia function
3 kinds of Freeze-dry Powder of Probioctics prepared by embodiment 1, i.e. Lactobacillus plantarum, lactobacillus acidophilus and animal bifidobacteria
The bacterium powder of lactic acid bacteria is 2 according to mass ratio:1:1 ratio carries out science compounding, is well mixed, and obtains final product with conditioning breast hyperplasia
The probiotic composition of function.
Embodiment 4：The preparation of the probiotics Chinese medicine preparation with conditioning breast hyperplasia function
Chinese medical extract prepared by probiotic composition and embodiment 2 prepared by embodiment 3 is crossed more than 100 mesh and sieved respectively
Son, and weigh standby, according to quality it is 2 by probiotic composition and Chinese medical extract：25 carry out dispensing.Each material will exist above
Fully mixed to uniform color in mixer, no color differnece obtains the probiotics Chinese medicine preparation with conditioning breast hyperplasia function.
Embodiment 5：The preparation of the product with conditioning breast hyperplasia function
Chinese medical extract prepared by the freeze-dried powder and embodiment 2 of probiotics prepared by embodiment 1 is crossed more than 100 mesh respectively
Sieve, and weigh standby；By mass percentage for probiotics dry powder 2% (viable count in probiotics dry powder for 8.0 ×
109Cfu/g), Chinese medical extract 25%, prebiotics 38%, the ratio of auxiliary material filler 35% carries out dispensing.Each material by more than
Fully mixed to uniform color in mixer, no color differnece obtains the product with conditioning breast hyperplasia function.
The prebiotics is by oligoisomaltose, FOS and xylo-oligosaccharide in mass ratio 4:3:1 composition.
The auxiliary material filler is citric acid.
Embodiment 6：Effect test
1. the structure of hyperplasia of mammary gland model, packet and administration：From the white mouse of female KM 60 of 20-22g, random point
It is 6 treatment groups, i.e. blank control group, model group, product low dose group (1/2 human body equivalent), (human body is equivalent for middle dose group
Amount), high dose group (5 times of human body equivalents), every group 10.In addition to blank group, remaining each group is combined with estrogen and progesterone
Hyperplasia of mammary gland model is replicated, concrete operations are as follows：With 0.5mgkg-1·d-1Give mouse continuous intraperitoneal injection oestradiol benzoate
20d, is changed to 5mgkg on the 21st day-1·d-1To the continuous intraperitoneal injection progesterone of mouse 5 days, control group was with same mL normal
Salt solution is continuously injected 25 days.
Start within 5th day control group and model group gives the distilled water of equivalent, sample low dose group, middle dose group and high dose
Group give respectively human body equivalent medicine (medicine used be embodiment 5 prepare product, human body consumption be 5g/d, foundation
Body surface area conversion mouse is administered daily dosage；Administered volume is 0.4mL/), successive administration 35d, after the 35th day administration 1h,
Eyeball takes blood, cuts open and kills mouse and take breast tissue.The result that mammary gland of mouse hyperplasia is treated to it is analyzed.
2. result of the test：
(1) to the influence of each internal organ index of model mice
The results are shown in Table 1.
Table 1：To the prebiotic function (x ± s, n=10) of mice viscera index
Note：A, b, c represent significant difference (0.01<P<0.05).
Result shows：Data above shows, liver is caused after modeling and uterus index increases, while spleen and thymus gland refer to
Number reduces.Each product group can recover each internal organ index.Particularly middle dose group, spleen, thymus index are closer to right
According to group, uterus index also has significant difference with model group ratio.Illustrate, middle dosage product group can significantly reduce modeling to device is immunized
Official and the injury of reproductive organs.
(2) to the influence of model mice Hormone traits
The results are shown in Table 2.
Table 2：Influence (x ± s, n=10) to each Hormone traits
Note：A, b, c represent significant difference (0.01<P<0.05).
Result shows：Mouse and control group ratio after modeling, serum estradiol (E2) content are significantly raised, and progesterone (P) contains
Amount is significantly reduced, and each product group can in various degree recover the hormonal readiness of mouse.Wherein, middle dose group and model group ratio, E2
Reduce 12.4%, P and increase 7.6%.Show that product prepared by the embodiment of the present invention 5 can recover mouse Estrogen and progestin balance,
The proliferation of mammary gland is controlled from root to develop.
(3) to the influence of model mice Antioxidant Indexes
The results are shown in Table 3.
Table 3：Influence (x ± s, n=10) to each Antioxidant Indexes
Note：A, b, c represent significant difference (0.01<P<0.05).
Research finds that when the proliferation of mammary gland occurs, patient's interior free yl increases, and causes body MDA to measure and raises, SOD activity
Decline.Therefore Antioxidant Indexes can also evaluate the recovery situation of the proliferation of mammary gland.As shown by data：MDA contains in Mice Body after modeling
Amount is significantly raised, and SOD contents are significantly reduced.Each product group can have been lifted anti-oxidative ability of mice.Particularly middle dosage
Group, with model group ratio, MDA contents reduce 31.8%, SOD contents and increase 53.5%.This shows, the product energy of middle dose group
It is obviously improved the oxidation resistance of disease mice.
(4) to the influence of model mice mammary structure
Result is shown in Fig. 1, as seen from Figure 1, model group and control group ratio, mammary gland alveolus increase, acinus increasing number, and
Visible secretion in acinus.Product group acinus has all recovered, particularly product middle dose group, and acinus quantity and size are close to right
According to group.Each group acinus number and diameter are counted afterwards, the results are shown in Table 4.
Table 4：Influence (x ± s, n=10) to mammary structure
Result shows：Each product group can reduce the acinus number in model mice leaflet, reduce acinus diameter, wherein,
Middle dose group most pronounced effects.Breast histological sections can intuitively show mammary gland inner case, and this experiment shows, the present invention is implemented
Product prepared by example 5 can effectively alleviate proliferation of mammary gland symptom, so as to play a part of to prevent and treat the proliferation of mammary gland.
Embodiment 7：
Hyperplasia of mammary gland model is built as described in Example 6, and is administered by the middle dosage in embodiment 6, institute's drug point
Not Wei embodiment 3 prepare probiotic composition and embodiment 4 prepare probiotics Chinese medicine preparation, observation administration after it is small to model
The influence of mouse mammary structure, the results are shown in Table 5.
Table 5：Influence (x ± s, n=10) to model mice mammary structure
As can be seen from Table 5, probiotic composition of the invention, probiotics Chinese medicine preparation can effectively alleviate the proliferation of mammary gland
Symptom, so as to play a part of to prevent and treat the proliferation of mammary gland, and, probiotics, Chinese medical extract and prebiotics component can play association
With the effect of synergy.
The preferred embodiment of the application is the foregoing is only, the application is not limited to, for the skill of this area
For art personnel, the application can have various modifications and variations.It is all within spirit herein and principle, made any repair
Change, equivalent, improvement etc., should be included within the protection domain of the application.
Claims (10)
1. a kind of probiotic composition with conditioning breast hyperplasia function, it is characterised in that by Lactobacillus plantarum, acidophilus breast bar
Bacterium and animal bifidobacteria are constituted；
In the probiotic composition, the content of Lactobacillus plantarum is 5 × 106-5×109CFU/g, the content of lactobacillus acidophilus is
2.5×106-2.5×109CFU/g, the content of animal bifidobacteria is 2.5 × 106-2.5×109CFU/g。
2. probiotic composition as claimed in claim 1, it is characterised in that in the probiotic composition, Lactobacillus plantarum,
The mass ratio of lactobacillus acidophilus and animal bifidobacteria is 2:1:1.
3. probiotic composition as claimed in claim 1, it is characterised in that the lactobacillus acidophilus is deposit number
CCTCCNO:Lactobacillus acidophilus (Lactobacillus acidophilus) BLCC2-0024 of M2015129；The plant breast
Bacillus is the Lactobacillus plantarum LP of deposit number CCTCC M2010150.
4. the preparation method of the probiotic composition described in any one of claim 1-3, it is characterised in that step is as follows：
(1) Lactobacillus plantarum, lactobacillus acidophilus and animal bifidobacteria are carried out into fermented and cultured respectively, thalline is dense in making zymotic fluid
Degree reaches exponential phase 0.5-2.0 × 109cfu/ml；
(2) zymotic fluid is centrifuged respectively, abandons supernatant, obtain the bacterium mud of Lactobacillus plantarum, lactobacillus acidophilus and animal bifidobacteria；
(3) bacterium mud is well mixed with freeze drying protectant, freeze-drying is obtained final product.
5. a kind of probiotics Chinese medicine preparation with conditioning breast hyperplasia function, it is characterised in that by claim any one of 1-3
Described probiotic composition and Chinese medical extract synergistic combination is formed；
The Chinese medical extract is made up of the bulk drug of following weight portion：
Ginseng 3-8 parts, Poria cocos 10-15 parts, kelp 10-12 parts, dried orange peel 8-12 parts.
6. probiotics Chinese medicine preparation according to claim 5, it is characterised in that the Chinese medical extract is by following weight portion
Bulk drug be made：
6 parts of ginseng, 12 parts of Poria cocos, 12 parts of kelp, 10 parts of dried orange peel.
7. the probiotics Chinese medicine preparation according to claim 5 or 6, it is characterised in that the Chinese medical extract is by such as lower section
Method is prepared from：
Ginseng, Poria cocos, kelp and dried orange peel are placed in 8-10 times of water and soak 40-60min, decocted, water continues to decoct 30- after opening
50min, is filtrated to get the first filtrate；The dregs of a decoction carry out secondary decoction with 6-8 times of water, and water continues to decoct 30-50min, filtering after opening
Obtain the second filtrate to be well mixed with the first filtrate, it is more than 30% to be concentrated into solid content, and spray drying is crushed, sieving,
Obtain final product Chinese medical extract.
8. probiotics Chinese medicine preparation according to claim 5, it is characterised in that the probiotic composition and traditional Chinese medicine extraction
The weight ratio of thing is (2-10)：(20-30).
9. in the probiotics described in probiotic composition described in any one of claim 1-3 and/or claim any one of 5-7
Purposes of the medicine preparation in the product with conditioning breast hyperplasia function is prepared.
10. a kind of product with conditioning breast hyperplasia function, it is characterised in that be made up of the component of following mass percent：
Probiotic composition 2-10%, Chinese medical extract 20-30%, prebiotics 30-40%, auxiliary material filler 30-40%；
The prebiotics is selected from one or more in oligoisomaltose, FOS and xylo-oligosaccharide；Preferably, the benefit
Raw unit is by oligoisomaltose, FOS and xylo-oligosaccharide in mass ratio 4:3:1 composition；
The auxiliary material filler is selected from one or more in maltodextrin, citric acid, fruit powder and sugar alcohol.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201710141647.XA CN106798755B (en) | 2017-03-10 | 2017-03-10 | Probiotic composition with function of conditioning hyperplasia of mammary glands and application thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201710141647.XA CN106798755B (en) | 2017-03-10 | 2017-03-10 | Probiotic composition with function of conditioning hyperplasia of mammary glands and application thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN106798755A true CN106798755A (en) | 2017-06-06 |
| CN106798755B CN106798755B (en) | 2020-09-15 |
Family
ID=58988857
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201710141647.XA Active CN106798755B (en) | 2017-03-10 | 2017-03-10 | Probiotic composition with function of conditioning hyperplasia of mammary glands and application thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN106798755B (en) |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN107668458A (en) * | 2017-09-19 | 2018-02-09 | 华南农业大学 | A kind of solid beverage for improving menalgia |
| CN109588724A (en) * | 2019-01-28 | 2019-04-09 | 江西美好时光生物科技有限公司 | A kind of probiotic powder and preparation method thereof improving stomach trouble |
| CN113249256A (en) * | 2021-05-18 | 2021-08-13 | 江南大学 | Lactobacillus plantarum for relieving estrogen-related metabolic disorder and obesity and application thereof |
| CN114921389A (en) * | 2022-07-20 | 2022-08-19 | 广东益可维生物技术有限公司 | Probiotic composition with female intestinal private part nursing and mammary gland anti-inflammatory effects and application thereof |
Citations (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1502251A (en) * | 2002-11-26 | 2004-06-09 | 陈克铨 | Composite baterial milk products and preparation proess thereof |
| CN103637213A (en) * | 2013-11-01 | 2014-03-19 | 胡安然 | Special meal for patients with gynopathy |
| CN104187640A (en) * | 2014-08-16 | 2014-12-10 | 胡安然 | Full-nutrition formula food suitable for people with hepatic depression syndrome |
| CN104519866A (en) * | 2011-01-28 | 2015-04-15 | 益生菌股份公司 | Effervescent composition in solid form for use in vaginal applications for the treatment of vaginal infections |
| CN104905263A (en) * | 2015-06-04 | 2015-09-16 | 深圳市正晟药业科技有限公司 | Flowering plant prebiotic product and preparation method thereof |
| CN104958663A (en) * | 2015-06-05 | 2015-10-07 | 卿龙集团有限公司 | Beverage capable of preventing hyperplasia of mammary glands and preparing method of beverage capable of preventing hyperplasia of mammary glands |
| CN106266496A (en) * | 2015-06-05 | 2017-01-04 | 唐家林 | A kind of Chinese medicine composition of preventing mammary gland hyperplasia |
| CN106420847A (en) * | 2016-06-30 | 2017-02-22 | 山东凤凰生物有限公司 | Composition for auxiliary protection of gastric mucosa and/or remission of gastrectasia and microecological preparation thereof |
-
2017
- 2017-03-10 CN CN201710141647.XA patent/CN106798755B/en active Active
Patent Citations (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1502251A (en) * | 2002-11-26 | 2004-06-09 | 陈克铨 | Composite baterial milk products and preparation proess thereof |
| CN104519866A (en) * | 2011-01-28 | 2015-04-15 | 益生菌股份公司 | Effervescent composition in solid form for use in vaginal applications for the treatment of vaginal infections |
| CN103637213A (en) * | 2013-11-01 | 2014-03-19 | 胡安然 | Special meal for patients with gynopathy |
| CN104187640A (en) * | 2014-08-16 | 2014-12-10 | 胡安然 | Full-nutrition formula food suitable for people with hepatic depression syndrome |
| CN104905263A (en) * | 2015-06-04 | 2015-09-16 | 深圳市正晟药业科技有限公司 | Flowering plant prebiotic product and preparation method thereof |
| CN104958663A (en) * | 2015-06-05 | 2015-10-07 | 卿龙集团有限公司 | Beverage capable of preventing hyperplasia of mammary glands and preparing method of beverage capable of preventing hyperplasia of mammary glands |
| CN106266496A (en) * | 2015-06-05 | 2017-01-04 | 唐家林 | A kind of Chinese medicine composition of preventing mammary gland hyperplasia |
| CN106420847A (en) * | 2016-06-30 | 2017-02-22 | 山东凤凰生物有限公司 | Composition for auxiliary protection of gastric mucosa and/or remission of gastrectasia and microecological preparation thereof |
Non-Patent Citations (2)
| Title |
|---|
| 胡献国: "***疾病蜜膏方", 《蜜蜂杂志》 * |
| 钱庭元等: "乳酪乳酸杆菌注射液治疗家兔乳腺增生症的疗效观察", 《中国医院药学杂志》 * |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN107668458A (en) * | 2017-09-19 | 2018-02-09 | 华南农业大学 | A kind of solid beverage for improving menalgia |
| CN109588724A (en) * | 2019-01-28 | 2019-04-09 | 江西美好时光生物科技有限公司 | A kind of probiotic powder and preparation method thereof improving stomach trouble |
| CN113249256A (en) * | 2021-05-18 | 2021-08-13 | 江南大学 | Lactobacillus plantarum for relieving estrogen-related metabolic disorder and obesity and application thereof |
| CN114921389A (en) * | 2022-07-20 | 2022-08-19 | 广东益可维生物技术有限公司 | Probiotic composition with female intestinal private part nursing and mammary gland anti-inflammatory effects and application thereof |
Also Published As
| Publication number | Publication date |
|---|---|
| CN106798755B (en) | 2020-09-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN105343133B (en) | A kind of compound probiotic that treating ulcerative colitis, drug and preparation method thereof | |
| CN104522815B (en) | A kind of probiotics fermention maca composition and its preparation method and application | |
| CN103829092B (en) | Traditional Chinese medicinal composition and feed for treating escherichia coli diarrhea of piglets | |
| CN108671135A (en) | A kind of Traditional Chinese medicine probiotic compound of conditioning insomnia and depression | |
| CN109481473A (en) | Application of the bacteroides fragilis extract in the drug or food of preparation prevention and treatment irritable bowel syndrome | |
| CN106692204B (en) | Probiotics composition for relieving or improving pelvic inflammation and preparation method thereof | |
| CN106798755A (en) | A kind of probiotic composition and its application with conditioning breast hyperplasia function | |
| CN105079450A (en) | Probiotics traditional Chinese medicine preparation for relieving yin-deficiency type constipation of elder people and preparing method and application of probiotics traditional Chinese medicine preparation | |
| WO2012097579A1 (en) | Pharmaceutical composition for treating melasma and preparation method therefor | |
| JP2004505625A (en) | Conversion and modification of natural drugs by co-fermentation culture of intestinal symbiotic organisms | |
| CN114774318B (en) | Application of lactobacillus paracasei in preparation of products for relieving anxiety and depression symptoms | |
| CN115120683A (en) | Raw material composition, traditional Chinese medicine fermentation product, preparation method and application thereof | |
| CN108785331A (en) | It is a kind of that there is qi-blood tonifying composition and its preparation method and application | |
| CN106165780A (en) | A kind of broiler Chinese medicine composite probiotics feed additive and preparation method thereof | |
| CN114921389A (en) | Probiotic composition with female intestinal private part nursing and mammary gland anti-inflammatory effects and application thereof | |
| CN106074975A (en) | A kind of compositions and the application in preparation improves the product of function of intestinal canal thereof | |
| CN106924477B (en) | Composite traditional Chinese medicine fermentation preparation produced by mixed bacteria fermentation and preparation method thereof | |
| CN106309506A (en) | Probiotic composition with menstruation regulating function and application thereof | |
| CN105797003A (en) | Probiotics fermentation traditional Chinese medicine compound composition for treating colorectal cancer and preparation method and application thereof | |
| CN107468999A (en) | A kind of fermentation composition with beauty treatment and eliminating spot function and preparation method thereof | |
| CN110801488A (en) | Combined prebiotics particle for regulating brain and intestine axis polysaccharide and preparation method and application thereof | |
| CN109897795A (en) | A kind of microbial bacterial agent and its application on anti-treat constipation | |
| CN105770525A (en) | Probiotic-fermented medicine-food dual purpose traditional Chinese medicine composition as well as preparation method and application thereof | |
| CN104997812A (en) | Drug for resisting cerebral ischemia-reperfusion injury as well as preparation method and application of drug | |
| CN104524162A (en) | Composite fermentation type traditional Chinese medicine for improving stress resistance of livestock and poultry and preparation method of composite fermentation type traditional Chinese medicine |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| TA01 | Transfer of patent application right | ||
| TA01 | Transfer of patent application right |
Effective date of registration: 20180803 Address after: 271000 Laboratory Building of Shandong Baolai Lilai Bioengineering Co., Ltd. south of Pioneering Street, Eastern New District, Taishan District, Tai'an City, Shandong Province Applicant after: Tai'an Da Fan Shennong biological Co., Ltd. Address before: 271600 Jinniu Mountain street, Tai'an, Shandong 001 Applicant before: Taian Dafan Shennong Pharmaceutical Co.,Ltd. |
|
| TA01 | Transfer of patent application right |
Effective date of registration: 20181226 Address after: 271021 Laboratory Building of Shandong Baolailailailailailailai Bioengineering Co., Ltd. to the south of Pioneering Avenue in Taishan District, Taian City, Shandong Province Applicant after: Shandong Shennong Hospital Management Co., Ltd. Address before: 271000 Laboratory Building of Shandong Baolai Lilai Bioengineering Co., Ltd. south of Pioneering Street, Eastern New District, Taishan District, Tai'an City, Shandong Province Applicant before: Tai'an Da Fan Shennong biological Co., Ltd. |
|
| TA01 | Transfer of patent application right | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant | ||
| TR01 | Transfer of patent right | ||
| TR01 | Transfer of patent right |
Effective date of registration: 20200904 Address after: 271021 Experimental Building of Shandong Baolailailailailailai Bioengineering Co., Ltd. to the South of Pioneering Street, East New District, Taishan District, Taian City, Shandong Province Patentee after: TAIAN DAFAN SHENNONG BIOLOGY Co.,Ltd. Address before: 271021 Laboratory Building of Shandong Baolai Lilai Bioengineering Co., Ltd. south of Pioneering Avenue, Eastern New District, Taishan District, Taian City, Shandong Province Patentee before: Shandong Shennong Hospital Management Co.,Ltd. |
|
| CP02 | Change in the address of a patent holder | ||
| CP02 | Change in the address of a patent holder |
Address after: 271000 first floor, No. 17, Huayuan Road, Shanggao street, Taishan District, Tai'an City, Shandong Province Patentee after: TAIAN DAFAN SHENNONG BIOLOGY Co.,Ltd. Address before: 271021 Experimental Building of Shandong Baolailailailailailai Bioengineering Co., Ltd. to the South of Pioneering Street, East New District, Taishan District, Taian City, Shandong Province Patentee before: TAIAN DAFAN SHENNONG BIOLOGY Co.,Ltd. |